Signatures and determinants for diagnosing infections and methods of use thereof

Patent metadata

Field	Value
Publication number	US-12188934-B2
Application number	US-202117507994-A
Country	US
Kind code	B2
Filing date	Oct 22, 2021
Priority date	Feb 9, 2012
Publication date	Jan 7, 2025
Grant date	Jan 7, 2025

Abstract

A kit is disclosed for distinguishing between bacterial and viral infections. One of the antibodies of the kit specifically binds to TNF-related apoptosis-inducing ligand (TRAIL) protein and another of the antibodies of the kit specifically binds to Procalcitonin (PCT) protein.

First claim

What is claimed is:

1. A kit comprising antibodies, at least one of said antibodies is a monoclonal antibody, wherein a first antibody of said antibodies specifically binds to TNF-related apoptosis-inducing ligand (TRAIL) protein, a second antibody of said antibodies specifically binds to Procalcitonin (PCT) protein, and a third antibody of said antibodies specifically binds to C-Reactive protein (CRP), wherein the kit does not comprise more than three additional antibodies which specifically bind to additional determinants, each of said three additional antibodies targeting a different soluble determinant of said additional determinants, wherein said determinant is a protein whose level is differentially expressed in a viral and bacterial infection.

2. A kit comprising antibodies immobilized on a solid support, wherein said antibodies consist of a first antibody that specifically binds to TRAIL protein, a second antibody that specifically binds to PCT protein and a third antibody that specifically binds to C-Reactive protein (CRP).

3. The kit of claim 1 , further comprising: (i) an antibody that specifically binds to said TRAIL protein at an additional site as to the site to which said first antibody binds; and (ii) an antibody that specifically binds to said PCT protein at an additional site as to the site to which said second antibody binds, wherein each of said antibodies of (i) and (ii) comprise a detectable label selected from the group consisting of a radioactive label, a fluorescent label, a chemiluminescent label, a colorimetric label and an enzyme.

4. The kit of claim 1 , wherein said first antibody and said second antibody are immobilized to a solid support.

5. The kit of claim 1 , wherein said first antibody and said second antibody are immobilized to a single solid support.

6. The kit of claim 2 , wherein each of said first antibody, said second antibody and said third antibody are immobilized to a single solid support.

7. The kit of claim 3 , wherein said enzyme is horseradish peroxidase or alkaline phosphatase.

8. The kit of claim 2 , being used in a lateral flow immunoassay.

Assignees

• Memed Diagnostics Ltd

Inventors

• Oved Kfir
• Eden Eran
• Ifergan Ilan

Classifications

• G01N33/6866

  Interferon · CPC title

• G01N27/44739

  Collecting the separated zones, e.g. blotting to a membrane or punching of gel spots · CPC title

• G01N27/44726

  using specific dyes, markers or binding molecules · CPC title

• G01N27/447

  using electrophoresis · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title